Physician profile
Colleen Ross
NPI 1700293859
$3,282.33
in general payments reported to CMS, 2019-2025
36 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $890 · 2023: $606 · 2024: $810 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.04 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $478.58 | 2022-2025 | Pemazyre, Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $319.70 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $276.17 | 2021-2025 | |
| Seagen INC. | $223.76 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Janssen Biotech, INC. | $168.30 | 2021-2025 | Darzalex, Carvykti, Talvey |
| Genzyme Corporation | $158.51 | 2021-2024 | |
| Lilly USA, LLC | $148.57 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $125.21 | 2021-2024 | Opdualag, Opdivo |
| Pfizer INC. | $123.95 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $120.04 | 2022-2025 | Clonoseq |
| Amgen INC. | $91.41 | 2021-2023 | Lumakras |
| Servier Pharmaceuticals LLC | $88.65 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $86.25 | 2021-2022 | |
| Tersera Therapeutics LLC | $77.58 | 2021-2024 | Zoladex |
| Karyopharm Therapeutics INC. | $76.07 | 2021-2024 | Xpovio |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $74.18 | 2024-2025 | Tecentriq |
| Abbvie INC. | $66.32 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $61.29 | 2022-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.61 | 2021-2023 | Fruzaqla |
| Ipsen Biopharmaceuticals, INC | $51.54 | 2021-2022 | |
| Stemline Therapeutics INC. | $44.39 | 2024-2025 | Orserdu |
| Celgene Corporation | $42.75 | 2023-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $42.50 | 2022-2025 | Padcev |
| Pharmaessentia USA Corporation | $37.24 | 2023 | Besremi |
| Gilead Sciences, INC. | $28.37 | 2021-2025 | Trodelvy |
| Blueprint Medicines Corporation | $25.81 | 2023 | Ayvakit |
| Coherus Oncology, INC. | $25.71 | 2022 | |
| Caris Mpi, INC. | $23.43 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $22.37 | 2025 | |
| Glaxosmithkline, LLC. | $20.26 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $19.28 | 2022 | |
| Eisai INC. | $19.13 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.56 | 2024 | |
| Kyowa Kirin, INC. | $16.18 | 2022 | |
| Puma Biotechnology, INC. | $13.61 | 2021 | |
| Taiho Oncology, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.